Dr. Jan Westerman
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 421
Licensed in Alabama since 1986, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
AL license 13090 (first issued 1986; active) · MD license D82312 -
Critical Care Medicine (Internal Medicine) Physician
NC license 32298
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Alabama Medical Center Florence, AL
- Walker Baptist Medical Center Jasper, AL
- North Alabama Shoals Hospital Muscle Shoals, AL
- Fayette Medical Center Fayette, AL
- North Mississippi Health Services - South Marion Winfield, AL
Medical groups
- Carolinas Medical Center (1,067 clinicians)
- Ecm Health Group LLC (140 clinicians)
- Pulmonary and Sleep Associates of Jasper, PC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 421
- Services billed
- 1,136
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 358 | 184 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 285 | 161 |
| X-ray of chest, 2 views | 157 | 144 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 140 | 130 |
| Test to examine how well the lungs exchange gases | 115 | 113 |
| Test to determine lung volumes using sensors | 111 | 110 |
| Established patient office or other outpatient visit, 30-39 minutes | 60 | 56 |
| New patient office or other outpatient visit, 45-59 minutes | 26 | 26 |
| Hospital discharge day management, 30 minutes or less | 23 | 22 |
| Test for exercise-induced lung stress | 21 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Jasper, AL | 117 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Jasper, AL | 111 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Jasper, AL | 101 |
| Azithromycin Other prescribers in Jasper, AL | 98 |
| Zolpidem Tartrate Other prescribers in Jasper, AL | 82 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Jasper, AL | 46 |
| Montelukast Sodium Other prescribers in Jasper, AL | 42 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Jasper, AL | 40 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Jasper, AL | 34 |
| Prolastin C (alpha-1-proteinase inhibitor) | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 12 payments worth $1,247 in total to this clinician.
| Olympus Corporation of The Americas | $1,148 |
|---|---|
| Inspire Medical Systems, Inc. | $23.12 |
| Grifols USA, LLC | $21.97 |
| GlaxoSmithKline, LLC. | $20.21 |
| Amgen Inc. | $19.24 |
| Vapotherm Inc | $14.96 |
| Travel and Lodging | $1,119 |
|---|---|
| Food and Beverage | $128 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Olympus Corporation of The Americas Jun 13, 2025 | Travel and Lodging Spiration Valve System · Endotherapy · travel to Minneapolis, MN · in-kind | $830 |
| Olympus Corporation of The Americas Jul 12, 2025 | Travel and Lodging Spiration Valve System · Endotherapy · travel to Minneapolis, MN · in-kind | $200 |
| Olympus Corporation of The Americas Jun 13, 2025 | Travel and Lodging Spiration Valve System · Endotherapy · travel to Minneapolis, MN · in-kind | $35.00 |
| Olympus Corporation of The Americas Jul 11, 2025 | Travel and Lodging Spiration Valve System · Endotherapy · travel to Minneapolis, MN · in-kind | $29.31 |
| Olympus Corporation of The Americas Jul 11, 2025 | Travel and Lodging Spiration Valve System · Endotherapy · travel to Minneapolis, MN · in-kind | $25.18 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $17,472 in research payments for these studies, mostly to the institutions running them.
- Ph III OLE of Astegolimab in COPD
Genentech, Inc. - A multi-center, randomized, double-blind, parallel-group, placebo-cont
GlaxoSmithKline, LLC. - Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Sanofi US Services Inc. · Completed · NCT04456673
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.